Regulatory Roundup: FDA Provides Online Course on its Drug-Regulation Activities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Provides Online Course on its Drug-Regulation Activities

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration's website now features a free online 90-minute training program on the “Past, Present, and Future of FDA Human Drug Regulation.” The mini web-seminar provides an overview of the agency’s activities, starting with why FDA was established. The course includes a series of information slides, audio presentations, and brief polling questions. At the end of the session, users can take a test to receive a continuing education (CE) certificate or a certificate of completion (non-CE). The online course covers the steps required to develop and market a new drug (as well as OTC, generic, and fast-track drugs), the role of the Center for Drug Evaluation and Research, and the Office of Generic Drugs, patents and market exclusivity, compliance and postapproval monitoring, and recent FDA initiatives such as the Sentinel System, the Critical Path initiative, emergency relief, and harmonization. The goal is to help physicians, industry, patients, healthcare providers, and consumers better understand FDA and its activities.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here